Press Releases

LEESBURG, Va., Feb. 10 /PRNewswire-FirstCall/ -- Shot Spirits Corporation (Pink Sheets: SSPT) is pleased to announce that the Company will be receiving revenues as a result of royalties generated from distribution sales of ShotPak® cocktails in the State of Georgia.   Beverage Pouch Group, LLC (BPG), with whom the Company has an ownership position in and strategic partnership with, reported that Savannah Distribution Co. Inc. of Savannah, GA has agreed to distribute the ShotPak® throughout the Georgia market. Shot Spirits generates additional revenue each time a new distributor is added.  As sales of the ShotPak® increase, the Company receives additional royalties and year end dividends. Georgia becomes the 11th state in the 24 state program to carry the 10 Ready-To-Drink cocktails in the patented "Green no Landfill" StandUp pouch with its easy tear feature.  

"There's lots of activity around our new pouch package and busy on-the-go consumers are always asking for something new. This is a fantastic product for the twenty-something on-the-go consumer segment to enjoy. Our Ready-To-Drink pouches stand out on the store shelves. Until now we have not really ventured outside the east coast, but we have seen a lot of national interest, which has been great," says R. Charles Murray, CEO of the Beverage Pouch Group.  

"The ShotPak® cocktails and all of Beverage Pouch Group's beverage product lines are making significant strides both in the United States and abroad.  We benefit each time a new distributor is added and we look forward to additional territories throughout 2010," stated Brian P. Barrett, President, CEO of Shot Spirits Corporation.

For more information on the ShotPak®, please go to www.shotpakinc.com .

About Shot Spirits Corporation:

Shot Spirits Corporation through its two wholly owned subsidiaries, Shot Spirits International and GuestMetrics, Inc., is focused on delivering products and services to the multi-billion dollar hospitality industry.  Shot Spirits International, through their partnership with Beverage Pouch Group, is an innovator in the beverage and service industry with the flavors of the ShotPak® brand.  ShotPak® Cocktails and STR8UP Spirits brands are packed in their patented "Green no Landfill" StandUp pouch with easy-tear open feature. Shot Spirits is focused on distribution in supermarkets, liquor stores, as well as bars, restaurants, and sporting venues across the globe.

Safe Harbor Statement:

The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimate," "project," "intend," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technological advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, and various other factors beyond the Company's control.

SOURCE Shot Spirits Corporation

NEW YORK, Feb. 10 /PRNewswire/ -- Bachelorette star Jillian Harris sat down with 24Savvy.com in her Chicago home to talk about sex and money, her famous hot dog theory, the in-laws, and the challenges of planning a wedding.

"I'm kind of a guy in the way that I don't actually care if I ever have a wedding," Jillian told host Kathleen Monteleone in 24Savvy.com's newest webisode, debuting today.

24Savvy.com is the new online destination for sharing tips and ideas to live a smarter, more creative life. 24Savvy.com also serves as a social community where users are encouraged to interact on every level, including commenting, voting, blogging, posting video and photos. All activities earn members points towards great prizes and the chance to opt-in for savvy gifts.

Jillian told 24Savvy.com it has been important to keep her relationship moving at a pace that is right for her. "One of the biggest things we need to accomplish is to slow down, which we don't know how to do, and I would love to learn how to do that better," Jillian said of her 2010 goals with fiance Ed Swiderski. "All my friends and family are really pushing for us to set a date and to plan the wedding, and it gets us excited, but then we're like, 'Wait, our life has moved so fast. Are we in a rush for this?'"

Jillian, who is working on a book about her hot dog theory for finding the right guy, said she hopes an iPhone app will be the next step. "How cool would this be? You see a guy putting mustard and sauerkraut and onions on his dog, in that order, you type it into your iPhone, and bling! It tells you if he's dateable or if you guys are compatible."

Jillian Harris is the featured guest this month on the 24Savvy.com webisode series. A new webisode will debut each Monday through March 1, featuring savvy tips on relationships, sex, the in-laws, and how to make a relationship last.

Previous 24Savvy.com webisodes have featured Margaret Colin of "Gossip Girl" and ongoing Oprah contributors Joe Lupo and Jesse Garza of Visual Therapy.

ABOUT 24/SAVVY

24/Savvy (www.24savvy.com) is a multimedia digital community dedicated to providing members with tools for savvier living. With editorial content, style news and reviews, gift giveaways and a webisode series produced by award-winning production company Mountain Lion Entertainment, 24/Savvy is the new online destination for living a smarter, more creative life.

Company founder Valerie Donati said, "A savvy mindset isn't about trading down, but trading off.

Savvy doesn't necessarily equal thrift, it just means playing it smart. 24/Savvy gives its members fun and inventive ways to live their smartest, most creative life, regardless of their income."

24/Savvy, It's About Your Lifestyle. Not Your Bank Balance.  

SOURCE 24Savvy.com

- Testosterone Phase II(b) Clinical Trial Nearing Completion

- Acquisition of Second Technology Platform

- Private Placement Recently Closed

TORONTO, Feb. 10 /PRNewswire/ - Trimel BioPharma Holdings Inc. is today providing an update on a number of operational items that have contributed significantly to advancing the Company and achieving its initial objectives. Trimel is now well positioned with multiple Localized Dosing Technology (LTD) platforms, a robust and rapidly advancing product pipeline, a dedicated facility to meet its clinical development and manufacturing requirements and has ready access to capital to meet its financial needs as it executes its Business Plan.

Testosterone Phase II(b) Clinical Trial Nearing Completion

Trimel BioPharma Holdings Inc. is developing a product to treat male hypogonadism (or "Low T"). Hypogonadism is a biochemical syndrome characterized by a deficiency in serum testosterone that can be either acquired or inherited and seriously affects the quality of life for those afflicted with the syndrome. Trimel's developmental product for hypogonadism is delivered utilizing a Bio-Adhesive Gel Nasal Deposit System. This unique delivery systems avoids transference issues that are associated with the current topical gel therapies and provides portability which is a significantly more convenient dosing regime versus most other products currently available in the marketplace.

Trimel's hypogonadism product, Compleo - which in Latin means "to bring man up to strength", is being developed initially for the North American and European markets. Sales of currently available treatments for hypogonadism in North America approximate $1 billion, where the estimated treatment ratio is only 10% of those afflicted, and the European market is approximately half the size the North American market.

Earlier this quarter, the ongoing Phase II(b) clinical trial for Compleo closed its input screening and it is expected that all subjects will complete dosing by the end of the quarter. No serious Adverse Events have been reported and early data indicates that the product is efficacious and meets the Food and Drug Administration's (FDA) clinical endpoints.

Trimel has exclusive rights to employ the Bio-Adhesive Gel Nasal Deposit System in four specific treatment areas including testosterone for males (above), in the Female Sexual Dysfunction therapeutic class where statistics reveal that 43% of women between the age of 18 and 59 suffer from various symptoms, for Parkinsonism and for an anxiety agent for the treatment of acute panic breakthrough disorder.

Second Technology Platform Acquired

In December of 2009, Trimel successfully acquired through the complete asset purchase of enabling technologies from Direct Haler A/S, a privately held Danish company. These technologies received the European Drug Delivery Devices Product Differentiation Innovation of the Year Award from Frost Sullivan for 2009. These technologies are focused on the delivery of pharmaceutical compounds through pulmonary inhalation and nasal dispersion systems that utilize unique patented dosing technologies. These technologies are applicable to numerous pharmaceutical compounds covering a wide variety of therapeutic classes.

These technologies provide patients with improved uptake of medication over current therapies. Key features of these technologies are: a) the Product dose is visible within the device and therefore patients can be assured that their required dose has been delivered; b) the dosage device is disposable and therefore there is no risk of re-infection; and c) the dose is deposited at the site of action which avoids many of the side effects associated with certain classes of drugs.

As part of the acquisition, Trimel has acquired three product candidates that are in clinical development. These product candidates are being developed to provide patients suffering from allergy or asthma with a unique treatment modality to dramatically improve their quality of life. Trimel is also exploring other product candidates in the areas of pain management and supportive cancer therapy.

Completion of Private Placement

Trimel recently completed an initial round of private equity financing. This financing was achieved through a limited offering that was only made available to Friends and Family and a very limited number of select exempt investors. The Company, through this offering, successfully raised over $4.5 million in new capital. Investors, including the Company's founder, have contributed approximately $18 million to the Company since inception, and this capital has enabled the Company to make the significant advancements as outlined above.

About Trimel

Trimel BioPharma Holdings Inc. is a privately held company focused on improving the utility of known pharmaceutical compounds by employing 21st century dosing technologies that are specifically designed to avoid first pass metabolism. These Localized Dosing Technologies (LDT) allow Trimel to precisely target the distribution of medication thereby circumventing the gastrointestinal tract and liver to improve patient outcomes and reduce side effects.

Trimel currently has three proprietary LDT platforms and is actively pursuing the development and application of these technologies with several high value high volume pharmaceutical compounds.

For media inquiries, please contact Bruce Brydon or Ken Howling at ir@trimelbiopharma.com or 416 679 0771.

For licensing inquiries, please contact John McCleery at johnmccleery@trimel.net.

www.trimelbiopharma.com

Caution Regarding Forward-Looking Information and "Safe Harbor" Statement

All statements, other than statements of historical facts, made in this press release are forward-looking statements and may be forward-looking information in accordance with applicable securities laws (collectively, "forward-looking statements"). These forward-looking statements relate to, among other things, the Company's objectives, goals, strategies, beliefs, intentions, plans, estimates, and outlook, including, without limitation, statements concerning the following:

    -   the state of the Company's product pipeline;

    -   the prospective benefits of product candidates in clinical
        development;

    -   the number of subjects and timing of completion of dosing in respect
        of the ongoing Phase II(b) clinical trials for Compleo.

Forward-looking statements are identified by words such as "believe", "anticipate", "estimate", "expect", "intend", "plan", "expect", "project", "may" and "will" and other similar expressions. Although not all forward-looking statements contain these identifying words, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. Although the Company has indicated certain of these statements set out herein, all of the statements in this press release that contain forward-looking statements are qualified by these cautionary statements.

Although the Company believes that the expectations reflected in any forward-looking statements made in this press release are reasonable, actual results may differ materially from those expressed, or implied, in such statements. Such forward-looking statements are based on a number of assumptions which may prove to be incorrect, including, but not limited to assumptions regarding: the regulatory and legislative environment; general commercial risks; the ability of the Corporation to establish and maintain a market for the Company's products; market and consumer acceptance; operations; profitability; the Company's reliance on third parties; attraction and retention of key employees and consultants; competition; intellectual property; product development; availability of raw materials; inventory valuation, obsolescence and spoilage; health and safety risks; information; acquisition of companies, assets or technologies; availability of credit; investment, borrowing and interest rates; and liability insurance.

Important risks and factors that could cause actual results to differ materially from expectations include: (a) that the Company is a start-up business with no demonstrated history of profitable operations and accordingly (i) there is uncertainty regarding the ability of the Company to ever achieve, sustain or increase profitability, and (ii) there is no assurance the Company will be able to fund its operations with existing capital, or that it will be able to raise additional capital to fund operations; (b) the Company's dependence on, and ability to attract and retain, key personnel; (c) that the Company is under the control of a single controlling shareholder; (d) the cost of any future acquisitions and the ability to integrate any acquired businesses; (e) contractual disagreements and negotiations with third parties; (f) difficulties obtaining necessary approvals for development of products from the U.S. Food and Drug Administration, the Canadian Therapeutic Products Directorate or other regulatory authorities; (g) the results of continuing and future safety and efficacy studies by industry and government agencies; (h) uncertainties associated with the development, acquisition and launch of new products; (i) acceptance and demand for new pharmaceutical products; (j) the impact of competitive products and pricing; (k) the availability of raw materials and finished products; (l) the unpredictability of protection afforded by any patents or other intellectual and proprietary property; (m) any claims for infringement of the intellectual property rights of others; (n) potential product liability; (o) reliance on key strategic alliances; (p) the general regulatory environment; (q) tax rate assumptions; (r) the outcome of legal proceedings; and (s) fluctuating operating results. The Company cautions that the foregoing list of important factors that may affect future results is not exhaustive. The Company does not undertake to update or revise any forward-looking statements, except as may be required by law.

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, any securities, and no offering of securities is currently being made or is intended.

SOURCE Trimel BioPharma Holdings Inc.